BioSpace News Archive

In a case study released October 23 by Oculus for Business from Facebook, Nimbus Therapeutics explains why they expect to save tens of thousands of dollars per year by investing in virtual reality (VR) hardware from Oculus and software from Nanome, Inc., and how the technology could potentially help increase their earnings by accelerating their timeline to market.

- Balanced immune response with strong induction of binding, and neutralizing antibodies and first indications of T cell activation - Quality of immune response comparable to recovered COVID-19 patients, closely mimicking immune response after natural COVID-19 infection

Company’s high-resolution preimplantation genetic testing platform enables discovery of unexpected - and unintended - CRISPR changes to human embryonic DNA.

PARI Pharma GmbH, a company focused on the development, manufacturing and commercialisation of advanced aerosol delivery systems based on eFlow Technology, announces the issue of the CE declaration of conformity for its optimised eFlow Technology LAMIRA Nebuliser System.

Nurami Medical, a medical device R&D company, which is developing a groundbreaking technology that facilitates post-surgical healing of soft tissue healing, has announced that it has completed a fundraising round of up to $6 million.

Eight COVID-19 + CRAB patients have received PhageBank™ therapy under FDA-approved emergency allowance, with more anticipated

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced it has expanded its presence in Coralville, Iowa through its partnership with Dermatology Associates, LLP.

On September 30, 2020, the U.S. Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (DHHS) awarded IHRC, Inc. a 5-year, indefinite delivery/indefinite quantity contract, with a ceiling value of $49.5 million to provide support to the Office of Laboratory Safety (OLS).

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the closing of its previously announced underwritten public offering of 5,111,110 shares of its common stock,

The life science company Sartorius successfully closed the acquisition of the Slovenian purification specialist BIA Separations.